about
Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.Tissue expression of interleukin 2 (IL-2) and IL-2 receptor (IL-2R(alpha)/CD25) in non-Hodgkin B-cell lymphomas in children: correlations with clinical data.Regional HLA differences in Poland and their effect on stem cell donor registry planning.Cytomegalovirus pneumonia as the first manifestation of severe combined immunodeficiency.Clinical and In Vitro Studies on Impact of High-Dose Etoposide Pharmacokinetics Prior Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia on the Risk of Post-Transplant Leukemia RelapseTreosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.Long-term brain structural magnetic resonance imaging and cognitive functioning in children treated for acute lymphoblastic leukemia with high-dose methotrexate chemotherapy alone or combined with CNS radiotherapy at reduced total dose to 12 Gy.High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes.Fertility preservation issues in pediatric hematopoietic stem cell transplantation: practical approaches from the consensus of the Pediatric Diseases Working Party of the EBMT and the International BFM Study Group.Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.Myeloid sarcoma in children - diagnostic and therapeutic difficulties.Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study.Remaining problems and controversies in the management of childhood head and neck soft tissue sarcomas: Retrospective (national) Multicenter Study of the Polish Pediatric Solid Tumors Group.Bacterial infections in pediatric hematopoietic stem cell transplantation recipients: incidence, epidemiology, and spectrum of pathogens: report of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation.Impairment of Immune Function in Children with Familial Hemophagocytic Lymphohistiocytosis.Micafungin in invasive fungal infections in children with acute leukemia or undergoing stem cell transplantation.Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.Adoptive therapy with donor lymphocyte infusion after allogenic hematopoietic SCT in pediatric patients.Individualized tumor response testing profile has a prognostic value in childhood acute leukemias: multicenter non-interventional long-term follow-up study.Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia.Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.Incidence of Infectious Complications in Children With Acute Lymphoblastic Leukemia Treated With Hematopoietic Stem Cell Transplantation.Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intravenous infusion of high-dose treosulfan prior to HSCT.Development of a Limited Sampling Strategy for the Estimation of Exposure to High-Dose Etoposide After Intravenous Infusion in Pediatric Patients.State-of-the-art fertility preservation in children and adolescents undergoing haematopoietic stem cell transplantation: a report on the expert meeting of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow TranPopulation pharmacokinetics of treosulfan and development of a limited sampling strategy in children prior to hematopoietic stem cell transplantation.Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients.Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation.Outcome of acute lymphoblastic leukemia in children with down syndrome-Polish pediatric leukemia and lymphoma study group report.Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate- to high-dose methotrexate.Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia.European Society for Blood and Marrow Transplantation Analysis of Treosulfan Conditioning Before Hematopoietic Stem Cell Transplantation in Children and Adolescents With Hematological Malignancies.Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives.Ph-negative isolated myeloid sarcoma with NPM1 gene mutation in adolescent with Ph-positive chronic myeloid leukemia in remission after treatment with allogeneic bone marrow transplantation and imatinib mesylate.Polymorphism of the thymidylate synthase gene and risk of relapse in childhood ALL.Effects of cyclosporin A on the activity of mouse natural killer cells and hybrid resistance.Concomitant EBV-related B-cell proliferation and juvenile myelomonocytic leukemia in a 2-year-old child
P50
Q33588450-136FDDF2-6721-4366-8E5F-9B12C759ECC9Q33609584-41D87275-668E-4D6E-A4B8-3F004878A693Q34998868-15616E4F-0EA1-4CC9-AA53-853AEF52FE82Q35631796-0737C5A0-9D3D-46A5-A580-75B781AFCD76Q36065491-D1E9D43C-0A55-4E88-98F6-09BA96F7EBBCQ37117637-F29DD6DE-6DB8-4D55-ACE9-F64851AA531BQ37315405-18F9B45F-A63B-4B8A-9C5C-68E0CDAF2D52Q37727506-BCD3861D-13BA-414D-807A-52D4C2C0EB5FQ37788219-66051F38-6835-47B3-ADF7-38891A7A7988Q38520096-938F14C6-7181-43EE-8E8E-4A129858DAA5Q38652761-27C07E6F-45E3-4281-B5B6-EAA12BC8C0EBQ39049336-9028ECE5-C532-4C19-8F63-D896008F48A5Q39151887-D48A3D72-4EA6-49F5-A15E-CCCE202B2DE6Q40401220-AA78C34B-C010-44F1-B8CD-740FA973599FQ40502295-879316FE-CEE5-411B-9BAE-3C3462D10EF4Q40593048-52839166-D3EC-4C74-B3EA-6C6992EBB947Q40751502-3033FDC6-72E5-4FE3-B3A5-79EDBD657E0BQ40790252-EB80E629-A9D1-496F-8C67-D7122EE04182Q41532474-E9FA77C1-C9CC-48DF-A794-3D1A817DD115Q44208467-A55351C7-82C2-47B7-B6BD-05FBCE5093BFQ45388674-30E76AFB-0837-4D0C-B70A-97C08E79A650Q46656670-4FC958E8-FCB9-4BD9-84CD-E7198D8555FEQ46904843-BF3283A4-8862-44CC-A2DB-77ED6810AA2CQ47576492-FCD4530C-65B2-4BCB-A46E-8DF2BE2DA269Q47962565-CB62E736-73A5-4DC7-B93D-BD9F65743630Q48028122-E10D9583-C0A2-426E-8E0A-8F8931341BE2Q48135567-EA4CDDCC-AC75-4C2F-A4C7-27A86D17F3C5Q48249281-FB09C8BB-638F-45FF-BED8-88E000AF495BQ48416390-ACBAB288-B89E-4A3B-96B3-597525F9D523Q48846219-2A1D1548-3CD3-4A2F-8697-661CF1F35D62Q49276207-555AAD2A-4248-4962-8AB1-7E1DC11957F9Q50079472-2BCCCE19-27A7-43FF-8EE2-0F07C2E7115CQ50102649-DE5108C8-BED4-4FB2-8ABB-C67DA6F70470Q50848271-48CC5A6A-D49D-453A-9BAA-38AE991607BDQ50854536-72C286D8-1513-4FB5-9216-D819478DE3A2Q52647269-4F7F41A2-3C15-45B5-8CC1-17DEC640A303Q54294058-DA9031B1-D214-4626-9E18-A95744708C6BQ54374230-14040764-BD99-4079-9178-07684BFEC8CEQ54424566-EA5A778E-D3E5-40D6-9509-9BB5EB70EF6AQ57235770-DBB70C3B-479B-4F15-B49F-C2B6BD2D38D7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Jacek Wachowiak
@ast
Jacek Wachowiak
@en
Jacek Wachowiak
@es
Jacek Wachowiak
@nl
Jacek Wachowiak
@sl
type
label
Jacek Wachowiak
@ast
Jacek Wachowiak
@en
Jacek Wachowiak
@es
Jacek Wachowiak
@nl
Jacek Wachowiak
@sl
prefLabel
Jacek Wachowiak
@ast
Jacek Wachowiak
@en
Jacek Wachowiak
@es
Jacek Wachowiak
@nl
Jacek Wachowiak
@sl
P214
P106
P1153
56265101500
P21
P214
P31
P496
0000-0002-4680-603X
P734
P735
P7859
viaf-161113009